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Abstract 
Because of their rapid onset of action and short therapeutic half-life, new oral anticoagulants 
(NOACs) may significantly simplify peri-procedural oral anti-coagulation management during 
cardiac implantable electronic device implant and trancatheter ablation procedures. The  
pharmacological properties of NOACs are reviewed to better comprehend how these drugs may 
best be managed in the setting of different electrophysiological procedures. These drugs radically 
differ from conventional vitamin K antagonists, but also possess distinctive pharmacokinetics and 
pharmacodynamics that distinguish one NOAC from the other. Clinical evidence on the use of 
NOACs during CIED implant and transcatheter ablation procedures is still limited, but, at the same 
time, is rapidly expanding; there is a great need for extensive data derived from randomized-
controlled trials and multicentre registries to better define the use of these drugs in interventional 
electrophysiology.  
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Anticoagulation management; electrophysiological procedures; CIED implant; pulmonary vein 
isolation; radiofrequency ablation.
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Introduction 
The latest ESC guidelines on atrial fibrillation management [1] emphasize the growing 
importance of chronic anti-coagulation therapy in the setting of non-valvular atrial fibrillation (AF) to 
prevent thromboembolic stroke, defined on the basis of CHA2DS2VASc score. The clinical 
implications of these recommendations are that indication for anti-coagulation treatment has 
markedly expanded, especially among younger patients with AF.  There is therefore a strong 
clinical mandate for the use of new oral anticoagulant drugs (NOACs) that are easier to manage 
than conventional vitamin K antagonists (VKAs). In this perspective, the therapeutic effectiveness 
of NOACs to prevent thromboembolic stroke combined with their good safety profile is of great 
interest. NOACs overcome some of the important limitations of VKA therapy, namely the long 
onset of action, prolonged half-life, as well as important interactions with other drugs and foods. 
These limitations become particularly relevant when VKA drugs must be managed in the peri-
operatory setting. Specifically, interventional electrophysiology is concerned with cardiac 
implantable electric device (CIED) positioning and transcatheter ablation to treat cardiac 
arrhythmias. Careful oral anti-coagulation management is required to limit the time in which the 
patient remains at risk of thromboembolic events, but also to avoid peri-procedural bleeding. The 
European Heart Rhythm Association (EHRA) has recently issued a practical guide for the use of 
NOACs in different clinical settings [2]. This document has elaborated general recommendations 
for the management of NOACs for patients undergoing elective surgery and other interventions, 
including cardiac implantable electronic device (CIED) placement and transcatheter ablation 
procedures. These recommendations do not consider the particularities of CIED placement and 
some transcatheter ablation procedures such pulmonary vein isolation or ventricular tachycardia 
ablation procedures. Moreover, these new drugs are considered  a class of new drugs with similar 
properties, that altogether differ substantially from conventional VKA; it is important to consider 
also that dabigatran, rivaroxaban,  apixaban, and edoxaban present different pharmacological 
properties and, at the same time, available clinical data on their use in interventional 
electrophysiology remains scanty for all except maybe dabigatran. .  
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Therefore, the peri-procedural use of NOACs in the clinical setting of electrophysiological 
procedures, specifically CIED implantation and transcatheter ablation, is reviewed.  
First, focus is placed on the pharmacological properties of NOACs  are outlined to better 
comprehend and define their use in peri-procedural EP interventions. Second, by reviewing 
literature data, suggestions are provided on how to best manage NOACs during CIED positioning 
and  in the peri-procedural setting of transcatheter ablation procedures.  
 
Mechanism of action and pharmacokinetics of NOACs 
 CHA2DS2VASc score is a validated tool to quantify stroke risk in patients with atrial 
fibrillation. VKAs are the standard treatment for patients with atrial fibrillation and have 
demonstrated efficacy in the prevention of stroke. On the other hand, VKAs have a narrow 
therapeutic window and their metabolism vary among patients, with different responses and 
interactions with foods and drugs. Moreover, patients under VKAs therapy need routine laboratory 
monitoring. Differing from VKAs, NOACs present selective mechanisms of action and more stable 
and predictable pharmacokinetics. These properties provide the basis to simplify peri-procedural 
anti-coagulation management in patients with non-valvular atrial fibrillation.   
 Dabigatran is a potent, competitive, reversible direct inhibitor of thrombin, and is the active 
form found in plasma [3](Figure 1). After oral administration, dabigatran etexilate is rapidly 
absorbed and, by hydrolysis converted to dabigatran. It acts by inhibiting free and clot tied 
thrombin and is also able to reduce platelet aggregation stimulated by thrombin, thus accounting 
for their more effective action compared to indirect thrombin inhibitors, such as unfractionated 
heparin, which cannot inhibit thrombin linked to fibrin [4]. After oral administration dabigatran 
etexilate is absorbed from gastrointestinal tract and rapidly metabolized to dabigatran, but the 
absolute bioavailability of the molecule is low, averaging around 6,5%. Following oral 
administration, plasma concentrations grow rapidly, with peak concentration (Cmax) reached within 
30 minutes after ingestion [5]. The administration of a meal does not appear to affect the 
bioavailability of dabigatran etexilate, but results in a delay of about two hours in the time required 
to reach the peak plasma concentration. Indipendently from concentration dabigatran etexilate is 
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bound to plasma binding proteins for about one third, with an half-life of approximately12-14 hours, 
which tends to be prolonged in patients with renal function impairment. Experimental studies, in 
fact, showed that dabigatran was largely eliminated by the kidneys (about 85%), while elimination 
through stools was estimated at 6% of the administered dose. Dabigatran is conjugated with 
formation of acylglucuronide, pharmacologically active and is eliminated primarily in the urine in 
unchanged form [6].  
Rivaroxaban is the first oral anticoagulant acting as a direct inhibitor of factor Xa [7]. The 
inhibition of factor Xa caused by the molecule blocks at the same time the intrinsic and the extrinsic 
pathway of the coagulation cascade, blocking both the formation of thrombin and the development 
of clots. Rivaroxaban has no inhibitory effect on thrombin  (activated factor II) and no actions on 
the aggregation of platelets [7,8]. After oral administration the drug is rapidly absorbed from the 
gastrointestinal tract. Absolute bioavailability is very high (80%), compared to that of dabigatran 
(3), with a peak concentration (Cmax) reached within 2-4 hours after tablet ingestion. Concomitant 
food intake does not affect drug’s concentrations, but affects the peak plasma concentration by a 
delay of 2 hours [9].  
The interindividual variability of the pharmacokinetics of rivaroxaban is between 30% and 
40%. Rivaroxaban is transported bound to plasma binding protein, particularly albumin, for about 
95% and is metabolized via CYP3A4, CYP2J2 and CYP-independent mechanisms. The half-life of 
the drug varies between 7 and 11 hours. About 50% of the drug is eliminated in the urine, with 30% 
of the administered dose excreted directly in the urine in unchanged form. The remaining 50% are 
excreted with stools [7].  
Similar to rivaroxaban, apixaban is a potent, reversible, direct and highly selective inhibitor 
of factor Xa. The molecule does not require antithrombin III for antithrombotic activity. Apixaban 
inhibits both free factor Xa than that associated with the clot. It’s also an inhibitor of prothombinase. 
The inhibition of factor Xa by the drug prevents the generation of thrombin and the development of 
thrombi. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet 
aggregation induced by thrombin. After oral administration apixaban is rapidly absorbed from the 
gastrointestinal tract, reaching maximum plasma concentration after 3-4 hours after ingestion. The 
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concomitant administration of food does not affect the molecule’s concentration. The bioavailability 
of apixaban is around 50% for doses up to 10 mg and is carried by plasma binding protein 
approximately for 87%. Differently from dabigatran and rivaroxaban, apixaban is excreted mainly 
with stools, and renal excretion accounts only for 27% of elimination. The half-life of apixaban is 
about 12 hours and is metabolized by CYP3A4 and CYP3A5. The major biotransformation 
reactions are hydroxylation at the 3-ossopiperidinil and O-demethylation and the molecule is a 
substrate of the transport protein, P-glycoprotein (P-gp) [10].   
Edoxaban is a potent, reversible direct inhibitor of factor Xa. It doesn’t inhibit platelets 
aggregation but  prevents platelets aggregation induced by thrombin. After oral administration 
edoxaban is rapidly absorbed by gastrointestinal tract. The effect of food on absorption is clinically 
irrelevant [11]. The bioavailability of the molecule is great and the short half-life is variable between 
9 and 11 hours [8,12]. The drug is eliminated through kidneys (about 33%) and stool (about 66%) 
[12]. Several clinical studies showed that edoxaban at both dose of 15 mg or 30 mg /die reduced 
the incidence of venous thromboembolism after elective surgery for total hip replacement with a 
rate of bleeding similar to placebo [13,14]. Higher dosage increased tendency to bleed when 
administered to patients with atrial fibrillation [14]. The Phase III ENGAGE -AF- TIMI48 compared 
edoxaban to warfarin in the prevention of thromboembolism in patients with atrial fibrillation, 
showing non-inferiority of this NOAC compared with warfarin [15].  
 In summary, NOACs share some common pharmacological properties providing for simpler 
and easier peri-procedural anti-coagulation management. Rapid and predictable pharmacokinetics, 
limited interactions with foods and other drugs, as well as the fact that regular therapeutic effect is 
ensured without the need for monitoring, represent clear advantages of NOACs over conventional 
VKAs (Table 1)[15-18]. However, because NOACs anticoagulation effects are not monitored, 
correct management of these drugs depends on ascertained patient compliance to therapy. 
Furthermore, in a surgical setting, it is important to consider that no antidote is readily available [1] 
capable of rapidly antagonizing the effects of these drugs. Aspects pertaining to NOAC therapy 
initiation, therapy management in particular situations or according to particular patient 
characteristics has been detailed in the EHRA practical document [2].  
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Peri-procedural management of NOACs in patients undergoing CIED implant 
 Many patients on chronic anticoagulant therapy undergo implantation or substitution of a 
permanent pacemaker (PM) or an implantable cardioverter defibrillator (ICD), collectively known as 
cardiovascular implantable electrical devices (CIED). The perioperative management of 
anticoagulation therapy in these patients is a challenge that requires balance between the risk of 
acute thrombosis and perioperative bleeding, particularly pocket hematoma.  
In this setting, the standard treatment has become to operate high-risk patients 
(CHA2DS2VASc score> 1) in uninterrupted warfarin with INR value within therapeutic range as 
opposed to heparin-bridging anticoagulation [25, 26]. The uninterrupted VKA approach has shown 
to consistently reduce pocket hematoma by 70% compared to bridging with heparin [19-21]. 
Continuing warfarin with a therapeutic international normalized ratio between 2-2.3 appears to be a 
safe and cost-effective approach for CIED surgery in most patients with moderate to high 
thromboembolic risk [19,20].  
EHRA practical guide considers CIED positioning as a low bleeding risk intervention and 
propose to hold NOAC, in normal conditions, ≥ 24 hours before the intervention [2]. The document 
is particularly sensitive to dosage adjustment of dabigatran according to renal impairment. No 
consideration is however given to the fact that apixaban, which presents a shorter half-life, may be 
managed with shorter suspension intervals. The recommendations issued by the document are 
mostly empirical since clinical data on bleeding risk of patients chronically anticoagulated with 
NOAC in the peri-procedural setting of CIED implant or substitution are scarce and mostly limited 
to single center studies with small patient cohorts. A prospective observational study by Rowley 
[22] considered 25 patients, who underwent CIED implantation and received dabigatran for 
anticoagulation, showed that during the period of observation, no thromboembolic or bleeding 
complications developed, with no major bleeding complications within 30 days from surgery. One 
minor bleeding event (4%) occurred within 30 days of surgery in 1 patient who was also under dual 
antiplatelet therapy. Another recent study [23] compared uninterrupted dabigatran (in 48 patients) 
with uninterrupted warfarin (195 patients) during CIED procedure and showed a comparable 
incidence of pocket hematoma (around 2% in each group) between the two groups.  
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Based on the pharmacological properties of NOACs outlined previously, a reasonable 
approach (Table 2) may consist in interrupting the drug 24 hours (at least 1 half-life) before the 
CIED procedure. In the absence of bleeding complications, NOAC anticoagulation is then resumed 
24 hours after the procedure. This simplified approach (Figure 2), similar to that already suggested 
by the EHRA document [2], limits the unprotected period to a maximum of 24-48 hours, while 
limiting potential increased bleeding complications in continuous anticoagulation conditions 
(uninterrupted warfarin or with LMWH bridging). Furthermore, this simple approach avoids the 
rapid bouts/surges of anti-coagulation characteristics of the heparin-bridging approach. At the 
actual state of knowledge, in contrast to what has been recently suggested [23], it may be prudent 
to avoid interventions under conditions of uninterrupted NOAC therapy. The absence of a readily-
available, rapid-acting antidote should be a deterrent to consider this approach.  
As already mentioned earlier, patients who undergo CIED implant are usually older patients 
with comorbidities, and therefore at increased bleeding and thromboembolic risk. The most sought 
for pharmacological properties should combine stable bioavailability, limited renal excretion as well 
as shorter half-life to limit the unprotected time frame of peri-operative thromboembolic risk, while, 
at the same time, containing bleeding risk. Taken together, apixaban presents more favourable 
pharmacokinetics compared to other NOACs (Table 1, Figure 2), because of its stable 
bioavailability, its limited renal excretion and shorter half-life. However, as already outlined above 
data on the use of apixaban in this setting is lacking and in the absence of clinical data these 
considerations remain speculative.  
 In summary, the pharmacological properties of NOACs make these drugs extremely 
appealing to use in the peri-procedural setting of CIED implant and substitution. Their use in this 
setting remains however ill-defined. Data derived from large clinical registries and randomized 
clinical trials (RCTs) are further needed to evaluate specifically safety of these drugs in this setting 
as well as defining which is the best and safest therapeutic regimen to follow for each NOAC. In 
the absence of such evidence, the use of NOACs in the peri-procedural setting of CIED 
procedures should be prudent, and confined to patients at moderately high thromboembolic risk. 
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Higher risk patients should be treated according to the well-established uninterrupted VKA 
approach as supported by a large body of clinical evidence [19,20].  
 
Peri-procedural management of NOACs in transcatheter ablation procedures 
The peri-procedural management of NOACs in transcatheter ablation procedures is still 
unclear. While anti-coagulation management in transcatheter ablation of arrhythmias in the right 
cardiac chambers is straightforward and follow what has been outlined for CIED positioning, 
because these ablation procedures are considered at low thromboembolic and bleeding risk [2]. 
Differently, more complex transcatheter ablation procedures such as pulmonary vein isolation and 
ventricular tachycardia ablation are considered high-risk procedures warranting careful 
anticoagulation therapy management [2].  
The role of NOACs for trancatheter ablation has mainly been investigated in the clinical 
setting of PVI for the treatment of AF. When considering a patient with AF for PVI ensuring 
appropriate anti-coagulation is mandatory. Transcatheter ablation aiming PVI carries an additional 
thromboembolic risk. PVI implicates a long transcatheter ablation procedure in which multiple 
radiofrequency lesions are applied in the left atrium. This procedure therefore involves possible 
thrombus formation on the catheters and guide sheaths, endothelial denudation, local tissue 
inflammation, possible dislodgement of unrecognized left atrial thrombus, char formation on the 
catheter tip, and possible de novo clot formation due to atrial stunning if sinus rhythm is restored 
during the procedure either during ablation or by means of electrical cardioversion. These 
additional potential intraprocedural factors are controlled through continuous and rigorous anti-
coagulation. It is now recommended to intervene under uninterrupted warfarin [1,24], with 
therapeutic INR, while administering intravenous heparin to maintain a level of ACT >300 seconds 
during the entire procedure. However, many centers continue to perform PVI under normal INR, 
with peri-procedural LMWH bridging. PVI also implicates double transeptal puncture and many RF 
lesions in the left-atrial cavity thus exposing the patient to risks of severe bleeding.  
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Knowledge on the use of NOACs in this setting remains rather limited, but is in rapid 
expansion (Tables 2 A and B). Most of the available evidence concerns dabigatran (Table 2 A)[25-
32] and, more recently, some evidence has emerged on the use of rivaroxaban (Table 2 B) [31-33]. 
Tables 2 A and B summarize the main findings of the principal studies who have investigated the 
use of these drugs in the context of PVI compared to uninterrupted warfarin, with particular 
emphasis placed on peri-procedural anticoagulation regimen. Based on the current clinical 
evidence, and consistent with NOACs’ pharmacological properties, the most common anti-
coagulation regimen using NOACs is as follows: the NOAC is held 1 half-life duration before PVI 
procedure, i.e. 12 hours for dabigatran and 24 hours for rivaroxaban; during PVI ACT is maintained 
≥ 300 seconds; the NOAC is resumed 4 hours after PVI procedure once hemostasis has been 
achieved.  For completeness, it is worth mentioning that other contributions have considered 
differing peri-procedural anti–coagulation regimens: Winkle and colleagues [34] compared peri-
procedural efficacy and safety of dabigatran in comparison, not to uninterrupted warfarin, but 
bridging regimen with unfractionated heparin (not cited in Table 2 A); other studies evaluated 
uninterrupted periprocedural anticoagulation regimen with NOACs [32,33]; in a recent RE-LY 
subanalysis the last dose of dabigatran was held a median of 49 hours before PVI procedure and 
not 12 hours before as is usually the case [35]. 
Overall, as detailed in Tables 2 A and B(25-, peri-procedural anticoagulation with NOACs in 
the setting of PVI has been demonstrated to be comparable to uninterrupted warfarin both in terms 
of efficacy as well as safety. This conclusion is in line with the findings of 2 recent meta-analysis 
studies [36-38]. In these contributions different peri-procedural anti-coagulation regimens in the 
setting of PVI were considered.   
Even though clinical evidence supporting the use of NOACS in the setting of PVI is rapidly 
expanding, there are several considerations to be made. First, as high-lighted in the tables the 
large body of evidence issued derives mainly from retrospective observational data and not 
multicentre randomized studies. In this regard it is important to point out that the only multi-center 
study [27] enrolling 290 patients treated with dabigatran 150 mg bid showed an increased risk of 
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bleeding and a trend towards an increase incidence of thromboembolic complications compared to 
uninterrupted warfarin. A possible explanation for these results may lie in the multicentric design of 
the study that introduces varying patient-specific, technical and operator-dependent characteristics 
which yield differing results compared to single-center studies (in which these variables are more 
“controllable”). In this contribution [27], some patients with persistent AF and dilated left atrium 
were considered; some of these patients underwent extensive ablation in the left atrium which 
consisted not only in PVI, but also applying lines on the roof of the left atrium and along the mitral 
isthmus. Second, most published data concern the use of dabigatran, while the available data 
concerning rivaroxaban is limited. It is interesting to point out that a similar multicenter randomized 
study by the same group as the multicenter study with dabigatran [33], resulted in similar efficacy 
and safety by using uninterrupted rivaroxaban compared to uninterrupted warfarin. Third, although 
no data are thus far available for apixaban or edoxaban, based on the pharmacological properties 
of each NOAC (Table 1), some suggestions on how to manage NOACs in patients undergoing an 
elective high-risk transcatheter ablation procedure are provided (Table 3).  
In summary, while the use of NOACs in this setting does look promising, as is the case for  
their use in CIED procedures, here too, there is a great need for further clinical evidence for their 
use derived from large multicenter registries and randomized clinical trials.  
Conclusions 
 There is no doubt that NOACs simplify oral anti-coagulation management of patients CIED 
procedures and trancatheter ablation procedures because of their rapid onset of action and short 
therapeutic half-life. However, until their use is not founded on the basis of solid multicentre data in 
specific settings such as peri-procedural management of CIED procedures and transcatheter 
ablation, some degree of caution is warranted for their use. Furthermore, there is little guidance on 
which NOAC to prescribe considering specific patient characteristics. The present guidelines 
consider NOACs as a distinct class of drugs, because these drugs radically differ from 
conventional VKA. However, as presented in this review the different NOAC agents each have 
specific pharmacokinetics and pharmacodynamics that may render the use of one agent rather 
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than another in specific patient sub-sets. In older patients with comorbidities or in ablation 
procedures involving persistent or long-standing atrial fibrillation, therapy with VKAs is well 
established and should still be considered as first-line treatment.  
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Table 1. New anticoagulant drugs approved for prevention of systemic embolism or stroke in 
patients with non-valvular atrial fibrillation. Modified from Heidbuchel et al (1). 
 
 Dabigatran Apixaban Rivaroxaban Edoxaban 
Action Direct thrombin 
inhibitor  
Activated factor Xa 
inhibitor 
Activated factor Xa 
inhibitor 
Activated factor 
Xa inhibitor 
Bioavailability 6% >50% >80% 60% 
Time to peak 
activity 
2 hours 3 hours 2-4 hours 1-2 hours 
Half-life 14-17 hours 5-9 hours (young), 
11-13 (eldery 
patients) 
8-15 hours 6-11 hours 
Dose 150 mg bid 
 
110 mg bid 
5 mg bid 
 
2,5 mg bid 
20 mg qd 
 
15 mg qd 
15 mg 
30 mg 
Interactions P-gp inhibitors 
and inducers 
CYP3A4 
inhibitors/inducers 
CYP3Aç inducers, 
CYP3A4 and P-gp 
inhibitors 
Potent inhibitor 
of Pgp 
Renal 
elimination 
80% 27% 33% 33% 
Studies RE-LY [16] ARISTOTLE [18] ROCKET-AF [17] ENGAGE [15] 
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Table 2. Peri-procedural management of NOACs for elective CIED implantation*.   
 
 
 Dabigatran Apixaban Edoxaban Rivaroxaban 
 Stopped     Resumed Stopped     Resumed No data Stopped     Resumed 
CrCl ≥ 80 ml/min ≥ 24h              ≥ 24h ≥ 24h             ≥ 24h No data ≥ 24h            ≥ 24h                
CrCl 50-80 ml/min ≥ 36h              ≥ 24h ≥ 24h             ≥ 24h No data ≥ 24h            ≥ 24h                
CrCl 30-50 ml/min ≥ 48h              ≥ 24h ≥ 24h             ≥ 24h No data ≥ 24h            ≥ 24h                
CrCl 15-30 ml/min Not indicated                ≥ 36h             ≥ 24h No data ≥ 36h            ≥ 24h                
CrCl < 15 ml/min Not indicated 
  
CrCl: Creatinine clearance. 
*Pacemaker or ICD implantation as well as electrophysiological study or radiofrequency catheter 
ablation for supraventricular tachycardia (including left-sided ablation via single transseptal 
puncture) are considered interventions with a low peri-procedural bleeding risk.  
Modified from reference [2]. 
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Table 3. Clinical evidence on the efficacy and safety of  peri-procedural anticoagulation regimen 
using dabigatran (A) or rivaroxaban in the setting of transcatheter ablation for atrial fibrillation 
compared to uninterrupted warfarin. Number represent absolute values with percentages between 
parenthesis.  
A) Dabigatran 
 
Study design NOAC regimen n. of 
dabigatran  
treated  
patients 
Thromboembolic 
events 
n (%) 
Major bleeding 
events 
n (%) 
Comments 
 
Retrospective 
observational 
(Kaseno et 
al)(25) 
 
-100 mg BID, 
held 12 h before; 
-ACT≥ 300 sec; 
-resumed 12-15 
h after. 
 
211 
 
0 (0) 
 
0 (0) 
 
/ 
 
Retrospective 
observational 
(Snipeliski et 
al)(26) 
 
-150 mg BID, 
held 12 h before; 
-ACT≥ 350 sec; 
-resumption? 
 
31 
 
0 (0) 
 
0 (0) 
 
Resumption 
unspecified  
 
Multicenter 
prospective 
(Lakkireddy et 
al )(27) 
 
-150 mg BID, 
held 12 h before; 
- ACT≥ 300 sec; 
- resumed 3 h 
after 
 
145 
 
3 (2.1) 
 
9 (6.2) 
 
Greater 
bleeding 
events 
compared to 
warfarin arm 
(p=0.019) 
 
Retrospective 
observational  
(Kim et al)(28) 
 
-150 mg BID, 
held 24 h before;  
- ACT≥ 300 sec; 
- resumed 4 h 
after. 
 
191 
 
0 (0) 
 
4 (2.1) 
 
No 
difference 
compared to 
warfarin 
 
Retropective 
observational 
(Maddox et 
al)(29) 
 
-150 mg BID, 
uninterrupted; 
-ACT≥ 350 sec; 
 
212 
 
1 (0) 
 
0 (0) 
 
No 
difference 
compared to 
warfarin 
 
Retrospective  
Observational 
(Bassiourny et 
al)(30) 
 
-150 mg BID, 
held 12-24 h 
before; 
-ACT≥350 sec; 
-resumed 3h 
after. 
 
344 
 
1 (0.3) 
 
4 (1.2) 
 
No 
difference 
compared to 
warfarin 
 
Retropective 
observational  
(Eitel et al, 
2013)(31) 
 
-150 mg BID, 
held 12 h before; 
-ACT≥350 sec; 
-resumed 4h 
after. 
 
144 
 
0 (0) 
 
0 (0) 
 
No 
difference 
compared to 
warfarin 
 
Retropective 
observational  
(Providencia, 
2014)(32) 
 
-150 mg BID, 
uninterrupted; 
- ACT ? 
 
176 
 
1 (0.6) 
 
2 (1.1) 
 
No 
difference 
compared to 
warfarin or 
rivaroxaban 
 
TOTAL 
  
1454 
 
6 (0.4) 
 
19 (1.3) 
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B) Rivaroxaban 
 
Study 
design 
NOAC 
regimen 
n. of 
rivaroxaban 
treated  
patients 
Thromboembolic 
events 
n (%) 
Major 
bleeding 
events 
n (%) 
Comments 
 
Retrospective 
observational 
(Eitel et al) 
(31) 
 
- 20 mg OD, held 
24 h before; 
-ACT≥ 300 sec; 
-resumed 12-15 
h after. 
 
16 
 
0 (0) 
 
0 (0) 
 
No 
difference 
compared to 
dabigatran 
or warfarin 
 
Multicenter 
prospective 
(Lakkireddy et 
al JACC 
2013)(33) 
 
-20 mg OD, 
uninterrupted; 
-ACT≥ 300 sec; 
 
 
321 
 
1 (0.3) 
 
5 (1.6) 
 
No 
difference 
compared to 
warfarin 
 
Retropective 
observational  
(Providencia, 
2014)(42) 
 
-15 mg OD, 
UninterrupTed; 
- ACT≥ 300 sec; 
 
 
188 
 
2 (1.1) 
 
3 (1.6) 
 
No 
difference 
compared to 
warfarin or 
dabigatran 
 
TOTAL 
  
525 
 
3 (0.6) 
 
8 (1.5) 
 
 
 
Table 3. Peri-procedural management of NOACs for elective high risk transcatheter ablation 
procedures*.   
 
 Dabigatran Apixaban** Edoxaban Rivaroxaban 
 Stopped     Resumed Stopped     Resumed No data Stopped     Resumed 
CrCl ≥ 80 ml/min 12-24h            ≥ 3h 12-24h          ≥ 3h No data 12-24h          ≥ 3h 
CrCl 50-80 ml/min ≥ 24h              ≥ 3h 12-24h          ≥ 3h No data 12-24h          ≥ 3h 
CrCl 30-50 ml/min ≥ 36h              ≥ 3h 12-24h          ≥ 3h              No data 12-24h          ≥ 3h              
CrCl 15-30 ml/min Not indicated                ≥ 24h            ≥ 3h              No data ≥ 24h            ≥ 3h              
CrCl < 15 ml/min Not indicated 
 
CrCl: Creatinine clearance. 
* Complex left-sided ablation (pulmonary vein isolation; ventricular tachycardia ablation) are 
considered interventions with a high peri-procedural bleeding risk. The time estimates of last intake 
and resumption of NOAC are derived specifically from the main literature data on NOAC 
management in the setting of PVI. 
** no specific data available data for complex ablation procedures; the time estimates provided for 
apixaban in the table are empirical.  
Modified from reference [2]. 
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Figure legends 
Figure 1. Mechanism(s) of action of new oral anticoagulants (NOACs) and vitamin K antagonists 
(VKAs) such as warfarin.  
 
Figure 2. Comparison of the time course of drug plasma concentrations between three NOACs 
and warfarin.  
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